Lambert-Eaton Myasthenic Syndrome and Dermatomyositis With Anti-TIF1-gamma Autoantibody: A Unique Association of Autoimmune Neuromuscular Conditions Without Malignancy.
Journal
Journal of clinical neuromuscular disease
ISSN: 1537-1611
Titre abrégé: J Clin Neuromuscul Dis
Pays: United States
ID NLM: 100887391
Informations de publication
Date de publication:
01 Mar 2021
01 Mar 2021
Historique:
entrez:
17
2
2021
pubmed:
18
2
2021
medline:
18
11
2021
Statut:
ppublish
Résumé
Lambert-Eaton myasthenic syndrome (LEMS) is a presynaptic neuromuscular junction disorder, and dermatomyositis (DM) is an idiopathic inflammatory myopathy. LEMS and DM are uncommon conditions that can present similarly and are often associated with autoantibodies. Concomitant LEMS and DM have only been reported a few times, and most of those cases were paraneoplastic. We present the first reported case of a patient with antivoltage gated calcium channel antibody positive LEMS who subsequently developed DM with antitranscription intermediary factor 1-gamma (anti-TIF1-γ) antibodies. Interestingly, both conditions occurred without evidence of malignancy. This diagnosis of LEMS and DM with characteristic clinical, electrodiagnostic, and histopathological evidence led to a beneficial modification of the patient's therapeutic regimen. Due to the fact that overlapping concurrent neuromuscular conditions are rare, a high clinical suspicion is needed to identify, evaluate (including appropriate cancer screenings), and appropriately treat these patients.
Identifiants
pubmed: 33596001
doi: 10.1097/CND.0000000000000318
pii: 00131402-202103000-00007
doi:
Substances chimiques
Autoantibodies
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
164-168Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med. 1995;332:1467–1474.
Zalewski NL, Lennon VA, Lachance DH, et al. P/Q- and N-type calcium-channel antibodies: oncological, neurological, and serological accompaniments. Muscle Nerve. 2016;54:220–227.
Abenroth DC, Smith AG, Greenlee JE, et al. Lambert-Eaton myasthenic syndrome: epidemiology and therapeutic response in the national veterans affairs population. Muscle Nerve. 2017;56:421–426.
Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001;357:96–100.
Best M, Molinari N, Chasset F, et al. Use of anti-transcriptional intermediary factor-1 gamma autoantibody in identifying adult dermatomyositis patients with cancer: a systematic review and meta-analysis. Acta Derm Venereol. 2019;99:256–262.
Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford). 2009;48:607–612.
Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54:3682–3689.
Selva-O'Callaghan A, Trallero-Araguás E, Grau-Junyent JM, et al. Malignancy and myositis: novel autoantibodies and new insights. Curr Opin Rheumatol. 2010;22:627–632.
Trallero-Araguás E, Rodrigo-Pendas JA, Selva-O'Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64:523–532.
Sanders DB. Lambert-Eaton myasthenic syndrome: diagnosis and treatment. Ann NY Acad Sci. 2003;998:500–508.
Schoser B, Eymard B, Datt J, et al. Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer. J Neurol. 2017;264:1854–1863.
Oddis CV, Conte CG, Steen VD, et al. Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J Rheumatol. 1990;17:1329–1334.
Dimachkie MM, Barohn RJ, Amato AA. Idiopathic inflammatory myopathies. Neurol Clin. 2014;32:595–628–vii.
Artigou C, Guerin JM, Wallach D, et al. Dermatomyositis and Lambert-Eaton syndrome. Association of 2 paraneoplastic muscular syndromes [in French]. Ann Dermatol Venereol. 1982;109:737–738.
Milanez FM, Pereira CA, Trindade PH, et al. Lung adenocarcinoma, dermatomyositis, and Lambert-Eaton myasthenic syndrome: a rare combination. J Bras Pneumol. 2008;34:333–336.
Mössner R, Tings T, Beckmann I, et al. A close look at autoimmune muscle disorders: association of Lambert-Eaton myasthenic syndrome with dermatomyositis. Scand J Rheumatol. 2004;33:271–275.
Dai Y, Li P, Yan S, et al. Lung squamous carcinoma with two paraneoplastic syndromes: dermatomyositis and Lambert-Eaton myasthenic syndrome. Clin Respir J. 2016;10:495–499.
Oh SJ. Myasthenia gravis Lambert-Eaton overlap syndrome. Muscle Nerve. 2016;53:20–26.
Huang K, Shojania K, Chapman K, et al. Concurrent inflammatory myopathy and myasthenia gravis with or without thymic pathology: a case series and literature review. Semin Arthritis Rheum. 2019;48:745–751.
Preston DC, Shapiro BE. Lambert-Eaton myasthenic syndrome. In: Preston DC, Shapiro BE, eds. Electromyography and Neuromuscular Disorders: Clinical-Electrophysiologic Coorelations. 3rd ed. Oxford, United Kingdom: Elsevier Inc; 2013:535–537.
Scola RH, Fabio FM, Ramos CS, et al. Lambert-Eaton myasthenic syndrome. Report of two cases. Arq Neuropsiquiatr. 1998;56:457–464.
Nozaki K, Pestronk A. High aldolase with normal creatine kinase in serum predicts a myopathy with perimysial pathology. J Neurol Neurosurg Psychiatry. 2009;80:904–908.
Targoff IN, Miller FW, Medsger TA, et al. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol. 1997;9:527–535.
Hida A, Yamashita T, Hosono Y, et al. Anti-TIF1-γ antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology. 2016;87:299–308.
Trallero-Araguás E, Labrado-Horrillo M, Selva-O'Callaghan A, et al. Cancer-associated myositis and anti-p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy. Medicine (Baltimore). 2010;89:47–52.
Oldroyd A, Sergeant JC, New P, et al. The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis. Rheumatology (Oxford). 2019;58:650–655.
Kesner VG, Oh SJ, Dimachkie MM, et al. Lambert-Eaton myasthenic syndrome. Neurol Clin. 2018;36:379–394.
Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol. 2011;18:19–e3.
Tiniakou E, Mammen AL. Idiopathic inflammatory myopathies and malignancy: a comprehensive review. Clin Rev Allergy Immunol. 2017;52:20–33.